Blood group antigen a and flow cytometric analysis in resected early-stage non-small cell lung cancer

被引:0
|
作者
Graziano, SL
Tatum, AH
Gonchoroff, NJ
Newman, NB
Kohman, LJ
机构
[1] VET AFFAIRS MED CTR,DEPT PATHOL,SYRACUSE,NY 13210
[2] VET AFFAIRS MED CTR,DEPT SURG,SYRACUSE,NY 13210
[3] SUNY HLTH SCI CTR,SYRACUSE,NY 13210
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The loss of blood group antigen A on tumor tissue has been reported to be a strong adverse prognostic marker for patients with resected non-small cell lung cancer (NSCLC), Results have varied with respect to the prognostic significance of flow cytometric data, We sought to confirm the prognostic significance of blood group antigen A loss and flow cytometry in a large cohort of patients with early-stage NSCLC. Two hundred and sixty patients with surgically resected stage I(n = 193) and II (rt = 67) NSCLC with at least a 5-year follow-up were identified, Using paraffin-embedded primary tumor, immunohistochemical stains for blood group antigen A were performed on 90 patients with blood type A or AB, The DNA index and percentage of cells in S phase were successfully obtained on 188 and 152 patients, respectively, The median survival time of the patients with primary tumors negative for blood group antigen A was 38 months (II = 36), compared with 98 months (n = 54) for those with antigen A-positive tumors (P < 0.01), The median disease-free survival times for antigen A-negative and -positive tumors were 26 months and 98 months, respectively (P < 0.01), The median survival time of the patients with aneuploid tumors was 51 months (n = 131), compared with 50 months (n = 57) for those with diploid tumors (P = 0.42), The median survival time of the patients with S phase >8% was 44 months (n = 105), compared with 60 months (n = 47) for those with S phase less than or equal to 8% (P = 0.18), Multivariate analysis showed that the loss of antigen A, higher N and T stages, and the presence of mucin predicted for poorer disease-free and overall survival, In the subgroup of patients with blood group A or AB, the loss of antigen was the most powerful negative predictor of survival, Aneuploidy and percentage of cells in S phase were not of prognostic significance in this group of patients with resected stage I and II NSCLC. The value of blood group antigen A analysis needs to be evaluated in larger and prospective studies of early-stage NSCLC, Alteration of blood group antigen cell surface expression may represent an important marker for more aggressive biological and metastatic behavior in NSCLC.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 50 条
  • [1] Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
    Burdett, Sarah
    Pignon, Jean Pierre
    Tierney, Jayne
    Tribodet, Helene
    Stewart, Lesley
    Le Pechoux, Cecile
    Auperin, Anne
    Le Chevalier, Thierry
    Stephens, Richard J.
    Arriagada, Rodrigo
    Higgins, Julian P. T.
    Johnson, David H.
    Van Meerbeeck, Jan
    Parmar, Mahesh K. B.
    Souhami, Robert L.
    Bergman, Bengt
    Douillard, Jean-Yves
    Dunant, Ariane
    Endo, Chiaki
    Girling, David
    Kato, Harubumi
    Keller, Steven M.
    Kimura, Hideki
    Knuuttila, Aija
    Kodama, Ken
    Komaki, Ritsuko
    Kris, Mark G.
    Lad, Thomas
    Mineo, Tommaso
    Piantadosi, Steven
    Rosell, Rafael
    Scagliotti, Giorgio
    Seymour, Lesley K.
    Shepherd, Frances A.
    Sylvester, Richard
    Tada, Hirohito
    Tanaka, Fumihiro
    Torri, Valter
    Waller, David
    Liang, Ying
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (03):
  • [2] Management of Early-Stage Resected Non-Small Cell Lung Cancer: Consensus Statement of the Lung cancer Consortium
    Allehebi, Ahmed
    Al Kattan, Khaled
    Al Rujaib, Mashael
    Al Dayel, Fouad
    Black, Edward
    Mahrous, Mervat
    AlNassar, Muath
    Al Hussaini, Hamed
    Al Twairgi, Abdullah
    Abdelhafeiz, Nafisa
    Al Omair, Ameen
    Al Shehri, Salem
    Al-Shamsi, Humaid O.
    Jazieh, Abdul Rahman
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 31
  • [3] Postoperative adjuvant therapy for completely resected early-stage non-small cell lung cancer
    Harubumi Kato
    Masahiro Tsuboi
    Yasufumi Kato
    Norihiko Ikeda
    Tetsuya Okunaka
    Chikuma Hamada
    International Journal of Clinical Oncology, 2005, 10 (3) : 157 - 164
  • [4] What Is Best Liquid Remnant for Resected Early-Stage Non-small Cell Lung Cancer?
    Lanuti, Michael
    ANNALS OF THORACIC SURGERY, 2024, 118 (05): : 1144 - 1145
  • [5] Early-stage non-small cell lung cancer: A SEER database analysis
    Ganti, A. K.
    Shostrom, V.
    Islam, K. M.
    Marr, A. S.
    Smith, L.
    Kessinger, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Role of circulating miRNAs as prognostic biomarkers in resected early-stage non-small cell lung cancer
    Ulivi, P.
    Petracci, E.
    Ludovini, V.
    Marisi, G.
    Delmonte, A.
    De Luigi, N.
    Calistri, D.
    Crino, L.
    Amadori, D.
    Chiari, R.
    Baglivo, S.
    Grignani, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] A clinical model to predict brain metastases in resected early-stage non-small cell lung cancer
    Wu, Dongsheng
    Huang, Yuchen
    Wang, Beinuo
    Zheng, Quan
    Wang, Tengyong
    Zhou, Jian
    Mei, Jiandong
    BMC CANCER, 2025, 25 (01)
  • [8] Analysis of outcomes in resected early-stage non-small cell lung cancer (NSCLC) with rare targetable driver mutations
    Ghazali, Nadia
    Feng, Jamie
    Hueniken, Katrina
    Waddell, Thomas K.
    Yasufuku, Kazuhiro
    Pierre, Andrew
    Donahoe, Laura
    Wakeam, Elliot
    Cypel, Marcelo
    Yeung, Jonathan
    Keshavjee, Shaf
    De Perrot, Marc
    Leighl, Natasha B.
    Liu, Geoffrey
    Bradbury, Penelope Ann
    Sacher, Adrian G.
    Eng, Lawson
    Stockley, Tracy
    Tsao, Ming Sound
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review
    Gallina, Filippo Tommaso
    Bertolaccini, Luca
    Forcella, Daniele
    Mohamed, Shehab
    Ceddia, Serena
    Melis, Enrico
    Fusco, Francesca
    Bardoni, Claudia
    Marinelli, Daniele
    Buglioni, Simonetta
    Visca, Paolo
    Cappuzzo, Federico
    Spaggiari, Lorenzo
    Facciolo, Francesco
    CANCERS, 2022, 14 (08)
  • [10] Adjuvant Therapy in Early-Stage Non-Small Cell Lung Cancer
    Serke, Monika
    CONTROVERSIES IN TREATMENT OF LUNG CANCER, 2010, 42 : 135 - 144